Boehringer Ingelheim GmbH's Respimat Inhaler Meets Safety Goal in Study

Published: Sep 03, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Boehringer Ingelheim GmbH said the Respimat smoker’s cough inhaler is as safe and effective as its older HandiHaler device, in a study intended to assure users that the new product doesn’t pose a greater risk of death. Dubbed Tiospir, the company-funded trial followed 17,135 patients with chronic obstructive pulmonary disease, or COPD, for an average of 2.3 years, according to an abstract of the study results published online today by the New England Journal of Medicine. Two groups of patients took Boehringer’s Spiriva drug at one of two doses from the Respimat mist inhaler. A third used the HandiHaler, which administers Spiriva in powder form.

Help employers find you! Check out all the jobs and post your resume.

Back to news